News Oncodesign Precision Medicine

Equities

ALOPM

FR001400CM63

Market Closed - Euronext Paris Other stock markets 11:35:27 2024-05-10 am EDT			5-day change	1st Jan Change
1.41 ^EUR	+0.71%		-1.74%	-22.10%

Jan. 25	Oncodesign Precision Medicine: fundraising on the horizon	CF
Jan. 25	Oncodesign Precision Medicine Receives ERDF Fund Totalling ?2.1 Million for its Comete Program	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Degroof Petercam Initiates Coverage of Oncodesign Precision Medicine	Apr. 18	BU
Oncodesign Precision Medicine (OPM) obtains €5.6 million in public funding for its DEMOCRITE program dedicated to the clinical development of OPM-101	Apr. 17	BU
OPM Publishes Its Annual Results for 2023 and Provides an Update on Its Clinical Developments	Mar. 26	BU
Oncodesign Precision Medicine : OPM publishes its annual results for 2023 and provides an update on its clinical developments	Mar. 26	PU
Oncodesign Precision Medicine: fundraising on the horizon	Jan. 25	CF
Oncodesign Precision Medicine Receives ERDF Fund Totalling ?2.1 Million for its Comete Program	Jan. 25	CI
Eurazeo acquires a stake in Oncodesign Services	Jan. 23	CF
Oncodesign Precision Medicine Société anonyme announced that it has received ?22 million in funding from Eurazeo SE and other investors	Jan. 22	CI
Oncodesign Precision Medicine Société anonyme acquired Zobio B.v.	Jan. 22	CI
Oncodesign Precision Medicine Obtains EUR6 Million Loan from Regional Banks	23-10-06	MT
Oncodesign Precision Medicine Announces Positive Interim Results of Its Phase 1 Study Evaluating OPM-101 in Healthy Volunteers	23-10-02	CI
Oncodesign Precision Medicine Société Anonyme Approves the Nomination of Florence Dupré to the Board of Directors	23-05-30	CI
Oncodesign Precision Medicine : OPM announces its 2022 results	23-04-13	PU
Oncodesign launches clinical trial in IBD	23-02-10	CF
Oncodesign Precision Medicine : OPM announces the initiation of Phase I of ODS-101	23-02-09	PU
Oncodesign Precision Medicine Announces Initiation of Phase I of its RIPK2 Inhibitor ODS-101, aNew Therapeutic Agent for IBD	23-02-09	CI
Edmond de Rothschild Equity Strategies Management III S.à.r.l acquired 61.58% stakes in Oncodesign Precision Medicine Société anonyme from Philippe Genne and other managers and minority shareholder.	22-10-18	CI
Oncodesign Precision Medicine to List Directly on Euronext Access + Paris	22-10-05	MT
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	22-10-04	CI
Oncodesign Société Anonyme completed the Spin-Off of Oncodesign Precision Medicine Société anonyme.	22-10-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oncodesign Precision Medicine

Equities

ALOPM

FR001400CM63

Summary

Filters